THIRD AMENDMENT TO RIGHTS AGREEMENT
THIRD AMENDMENT TO RIGHTS AGREEMENT
This Third Amendment to Rights Agreement (this Amendment) is entered into effective as of August 26, 2009 (the Effective Date) by and between ADVENTRX Pharmaceuticals, Inc., a Delaware corporation (the Company), and Icahn Partners LP, Icahn Partners Master Fund LP and High River Limited Partnership (collectively, the Icahn Purchasers).
WHEREAS, the Company, the Icahn Purchasers and Viking Global Equities LP and VGE III Portfolio Ltd. (collectively, the Viking Purchasers and, together with the Icahn Purchasers, the Purchasers) are parties to that certain Rights Agreement, with an effective date of July 27, 2005, as amended (the Rights Agreement), pursuant to which the Company agreed to set the authorized number of directors constituting the Companys board of directors at 6 and to not change such number, except as set forth in the Rights Agreement;
WHEREAS, pursuant to Section 6.2 of the Rights Agreement, any term of the Rights Agreement may be amended with the written consent of the Company and the Icahn Purchasers;
NOW, THEREFORE, in consideration of both the foregoing premises and the terms and conditions set forth below, the Company and the Icahn Purchasers hereby agree as follows:
1. Board of Directors. The first sentence of Section 4 of the Rights Agreement is hereby amended and restated to read in its entirety as follows:
Effective promptly following the Closing, the Company shall set the authorized number of Board directors at six and the Company shall appoint a person suggested by the Purchasers which at the time own a majority of the Purchased Shares (the Purchaser Designee) to the vacancy so created; provided, however, that such person, if anyone other than Mr. Carl Icahn, would not subject the Company to making any disclosures under Item 401(f) of SEC Regulation S-K in any proxy statement (the Criteria); provided, further, that, in the event a director resigns from the Board and any resulting vacancy is not filled by a majority of the Board directors then in office, which majority includes the Purchaser Designee, if there is then a Purchaser Designee, the Board may decrease the authorized number of Board directors to the number of Board directors then in office (including for this purpose the appointment of a director to fill any vacancy resulting from such resignation); provided, further, that, from time to time, the Board may increase the number of authorized Board directors provided that any vacancy created by such an increase is filled by a majority of the Board directors then in office, which majority includes the Purchaser Designee, if there is then a Purchaser Designee.
2. Conflicts. Except to the extent amended herein, the Rights Agreement remains in full force and effect.
3. Governing Law. This Amendment will be governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be fully performed therein.
[Signature page follows]
IN WITNESS WHEREOF, the Company and the Icahn Purchasers have executed this Third Amendment to Rights Agreement effective as of the Effective Date.
COMPANY: | ADVENTRX PHARMACEUTICALS, INC. | |||||||||
By: /s/ Patrick Keran | ||||||||||
Name: | Patrick Keran | |||||||||
Title: | Vice President, Legal | |||||||||
ICAHN PURCHASERS: | ICAHN PARTNERS LP | |||||||||
By: | /s/ [illegible] | |||||||||
(Authorized Signatory) |
ICAHN PARTNERS MASTER FUND LP
By: | /s/ [illegible] | |||||
(Authorized Signatory) |
HIGH RIVER LIMITED PARTNERSHIP
By: Hooper Investments LLC, its general partner
By: Barbery Corp, its member
By: | /s/ [illegible] | |||||
(Authorized Signatory) |